Hoang Laura L, Tang Ping, Hicks David G, Chen Huijiao, Yang Qi, Haas Thomas S, Bremer Ryan E, Tacha David
*Department of Research and Development, Biocare Medical LLC, Concord, CA †University of Rochester Medical Center, Rochester, NY ‡Mercy Health System, Janesville, WI.
Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):606-12. doi: 10.1097/PAI.0b013e3182a4edef.
Immunohistochemical studies have shown E-cadherin to be expressed in breast carcinomas showing a ductal histology, with a corresponding loss of expression in tumors with a lobular histology. As a result, mouse monoclonal anti-E-cadherin [HECD-1] has been used by pathologists to differentiate between ductal and lobular carcinomas, with currently published sensitivity and specificity rates of approximately 90%. Rabbit monoclonal antibodies may combine the best properties of both mouse monoclonal antibodies and rabbit antisera. Therefore, this study compares the staining sensitivity and specificity of a new rabbit monoclonal E-cadherin and the standard mouse monoclonal E-cadherin [HECD-1] in breast ductal carcinomas, and evaluates a cocktail of rabbit monoclonal E-cadherin and p120 catenin in the discrimination of ductal from lobular carcinomas. The rabbit E-cadherin showed sharper staining and increased sensitivity (80/81, 99%) than the mouse E-cadherin (75/81, 93%). The rabbit E-cadherin achieved a score of 3+ in 85.2% (69/81) of cases as compared with a 3+ in only 21.0% (17/81) of cases stained with mouse E-cadherin. All lobular carcinomas (n=37) were confirmed by the absence of E-cadherin and the diffuse cytoplasmic expression of p120 catenin. Although both the single mouse E-cadherin and dual stain can differentiate ductal from lobular lesions, the dual stain is helpful in challenging cases because of its bright pink p120 catenin and dark brown rabbit E-cadherin staining. The highly sensitive rabbit E-cadherin antibody is the preferred antibody for evaluating ductal carcinomas and for distinguishing ductal versus lobular lesions, and the dual stain was superior to the single E-cadherin stain.
免疫组织化学研究表明，E-钙黏蛋白在具有导管组织学特征的乳腺癌中表达，而在具有小叶组织学特征的肿瘤中表达相应缺失。因此，病理学家使用小鼠单克隆抗E-钙黏蛋白[HECD-1]来区分导管癌和小叶癌，目前公布的灵敏度和特异度约为90%。兔单克隆抗体可能兼具小鼠单克隆抗体和兔抗血清的最佳特性。因此，本研究比较了一种新型兔单克隆E-钙黏蛋白和标准小鼠单克隆E-钙黏蛋白[HECD-1]在乳腺导管癌中的染色灵敏度和特异度，并评估了兔单克隆E-钙黏蛋白和p120连环蛋白混合物在区分导管癌和小叶癌方面的作用。兔E-钙黏蛋白显示出比小鼠E-钙黏蛋白（75/81，93%）更清晰的染色和更高的灵敏度（80/81，99%）。兔E-钙黏蛋白在85.2%（69/81）的病例中评分为3+，而小鼠E-钙黏蛋白染色的病例中只有21.0%（17/81）评分为3+。所有小叶癌（n=37）均通过E-钙黏蛋白缺失和p120连环蛋白的弥漫性细胞质表达得以证实。虽然单克隆小鼠E-钙黏蛋白染色和双重染色均可区分导管性和小叶性病变，但双重染色因其p120连环蛋白呈亮粉色、兔E-钙黏蛋白呈深棕色，在疑难病例中很有帮助。高灵敏度的兔E-钙黏蛋白抗体是评估导管癌和区分导管性与小叶性病变的首选抗体，双重染色优于单克隆E-钙黏蛋白染色。
